127697.1.
(a) CHHSA may enter into partnerships for the manufacture or purchase of any United States Food and Drug Administration (FDA)-approved point-of-care tests for fentanyl. Partnerships entered into pursuant to this section may allow the development, manufacturing, or distribution of FDA-approved point-of-care tests for fentanyl by any entity that is authorized to do so under federal or state law. (b) For purposes of this section, “point-of-care test for fentanyl” means a point-of-care test for use to detect if a person has consumed fentanyl. A point-of-care test for fentanyl includes, but is not limited to, a fentanyl test strip used to detect fentanyl in urine.